Q-omics provides the consensus-scored PTCHD1-AS profile across patient tissues and cancer cell-line models. PTCHD1-AS expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTCHD1-AS is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, PTCHD1-AS RNA expression shows 12,976 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, BRCA, and TGCT as cancer lineages where PTCHD1-AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTCHD1-AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTCHD1-AS survival associations across molecular data types. PTCHD1-AS RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTCHD1-AS RNA expression–survival associations across cancer types. High PTCHD1-AS expression shows unfavorable associations in LGG, UVM and UCEC, but favorable associations in HNSC, UCS and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for PTCHD1-AS RNA expression.
This table summarizes PTCHD1-AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PTCHD1-AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTCHD1-AS shows lower tumor expression in BRCA, KICH, COAD, BLCA and STAD and higher tumor expression in KIRP. The BRCA box plot shows higher PTCHD1-AS RNA expression in normal versus tumor tissue (log2 FC = −0.283, t-test p < 0.001).
This table shows molecular features associated with PTCHD1-AS in patient tissues and cancer cell lines. In patient samples, PTCHD1-AS shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
